Key result
Esmolol, an ultrashort-acting cardioselective beta-blocker with a nine-minute half-life, allows rapid titration and reversal of pharmacological effects in critically ill patients.
Population
Critically ill patients with cardiovascular diseases, including supraventricular tachycardia
Design
Review
Authors
Loading...
May enable precise beta-blockade in unstable patients; hypothesis-generating pending randomized outcome data.
The ultrashort duration of action of esmolol and flestolol allows for precise titration and rapid reversal of beta-blockade, expanding their utility in critically ill patients.
Murthy et al. (1988) conducted a review in Supraventricular tachycardia and cardiovascular diseases. Esmolol and Flestolol was evaluated. Esmolol, an ultrashort-acting cardioselective beta-blocker with a nine-minute half-life, allows rapid titration and reversal of pharmacological effects in critically ill patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: